

Substance Use Disorders and HIV

Updated: September 24, 2026

Reviewed: September 24, 2026

Key Considerations and Recommendations
<ul style="list-style-type: none">SUDs are prevalent among people with HIV and contribute to poor health outcomes; therefore, screening for SUDs should be a routine part of clinical care (AII).The most commonly used substances among people with HIV include the following (listed in alphabetical order): alcohol, benzodiazepines, cannabis/cannabinoids, club drugs, opioids, stimulants (cocaine and methamphetamines), and tobacco.Health care providers should be nonjudgmental when addressing substance use with people who have HIV (AIII).People with HIV and SUDs should be screened for additional mental health disorders (AII).People with HIV and SUDs should be offered evidence-based pharmacotherapy (e.g., opioid agonist therapy, tobacco cessation treatment, alcohol use disorder treatment) as part of comprehensive HIV care in clinical settings (see Table 16) (AI).ART is recommended for all people with HIV (AI). Ongoing substance use is not a contraindication to ART. People who use substances can achieve and maintain viral suppression with ART.Substance use may increase the likelihood of HIV transmission risk behaviors, the potential for drug–drug interactions, and the risk or severity of substance-associated adverse events (e.g., increased hepatotoxicity, neurocognitive impairment, overdose).Selection of ARV regimens for individuals with SUDs should take into account potential adherence barriers, comorbidities that could impact care (e.g., advanced liver disease from alcohol or hepatitis viruses), potential drug–drug interactions, and possible adverse effects of ART or substance use.Once-daily ARV regimens (ideally as a single-tablet regimen) with high barriers to resistance, low hepatotoxicity, and low potential for drug–drug interactions are preferred for people with SUDs (AIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Weak
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Key: ART = antiretroviral therapy; ARV = antiretroviral; SUD = substance use disorder

Background on Substance Use Disorders Among People With HIV

Ending the HIV epidemic requires addressing substance use among people with HIV, which poses a barrier to optimal engagement in the HIV care continuum. Ongoing substance use may prevent an individual from being tested for HIV, initiating antiretroviral therapy (ART), adhering to ART, **or remaining engaged in care**. Substance use may also increase the likelihood of risk-taking behaviors (e.g., sexual transmission risk behaviors, needle sharing, injection of substances), the potential for drug–drug interactions, and the risk or severity of substance-related adverse events (e.g., increased hepatotoxicity, **neurocognitive impairment**, overdose). In the United States, the death toll for drug overdose (102,123 deaths as of February 2024)¹ far exceeds the death toll for HIV (**4,296 deaths in 2024**).² Given the expanding overdose epidemic and the impacts of both substance use and substance use disorders (SUDs) on optimal engagement in the HIV care continuum, health care providers need a basic understanding of how to screen for and treat SUDs in people with HIV in clinical settings.³ **As SUDs are prevalent among people with HIV and contribute to poor health**

outcomes, screening for SUDs should be a routine part of clinical care **(AII)**. Additionally, people with HIV and SUDs should be screened for mental health disorders **(AII)**.

Substance use exists on a continuum, from episodic use to SUD, with its concomitant negative consequences. Research on alcohol consumption has defined a threshold at which consumption does not reach a diagnosis of SUD but where the level of consumption is nonetheless hazardous to the person. This level of consumption has been defined as at-risk or hazardous use. A comparable category does not exist for other substances. The prevalence of substance use and SUDs is higher among people with HIV than among the general public,⁴ and polysubstance use is common,⁵ including among adolescents and young adults with HIV (see [Adolescents and Young Adults With HIV](#)). This section focuses on the most commonly used substances among people with HIV (listed in alphabetical order): alcohol, benzodiazepines, cannabis/cannabinoids, club drugs,⁶ opioids, stimulants (cocaine and methamphetamines), and tobacco. Additionally, two common opioid adulterants (i.e., xylazine and medetomidine) with potential health consequences are also discussed.

People with HIV may use more than one substance and may not be ready to consider reducing the use of substances or seeking treatment for SUDs. Polysubstance use occurs for multiple reasons, including to improve the euphoria associated with use (e.g., use of cocaine and heroin mixtures called “speedballs”) and to reduce the adverse effects of a particular substance (e.g., the use of alcohol or benzodiazepines to reduce the anxiety caused by cocaine use).

Substance Use and Sexual Risk-Taking

A growing body of literature describes the intersection of substance use and sexual risk-taking, whereby drugs are intentionally used to enhance sexual activity (i.e., chemsex and sexualized drug use).⁷ Studies have investigated various substances used to enhance sexual pleasure, decrease inhibitions related to particular sexual acts, and combat low self-esteem. In a retrospective study in a London sexual health clinic, individuals who disclosed substance use (463 of 1,734 participants) had higher odds of acquiring new HIV infection, bacterial sexually transmitted infections (STIs), and/or hepatitis C virus (HCV).⁸ A much larger analysis using the European Men Who Have Sex With Men (MSM) Internet Survey, which collected data from 16,065 United Kingdom–based respondents, found that MSM who reported using methamphetamines or gamma-hydroxybutyrate (GHB) during the previous year were more likely to have gonorrhea infection than MSM who did not use these drugs, with odds ratios of 1.92 and 2.23, respectively.⁹ Between 2017 and 2020, the American Men’s Internet Survey collected data on chemsex drug use among MSM in the United States over the preceding 12 months. Of 30,294 MSM respondents, 3,113 (10.3%) self-reported chemsex in the past 12 months, with 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) (65.1%), methamphetamine (42.5%), and GHB (21.7%) being the top drugs reported for use.¹⁰ A recent study in Spain using an online, self-administered questionnaire found that 81.4% of 2,919 MSM attending four HIV/STI testing sites in Madrid and Barcelona had ever used any drug, and 50% had engaged in chemsex in the past 12 months. Of those engaging in chemsex, half engaged in condomless anal sex.¹¹ These data emphasize the need to screen people with HIV for substance use and STIs in clinical settings and to discuss strategies with these individuals to reduce potential harm.^{12,13}

Substance Use and Unstable Housing

People with HIV who inject drugs are more likely to be unhoused compared to those who do not inject drugs.¹⁴ Houselessness among people who inject drugs is associated with an increased risk of HIV acquisition.¹⁵

Among people with HIV and SUD, houselessness confers an increased risk for disruptions in the HIV care continuum independent of ongoing substance use. In a longitudinal study of people with HIV

who used drugs, adjusted for multiple intersecting risks—including unhealthy alcohol use, other substance use, incarceration, unemployment, education, age, sex, and race/ethnicity—houselessness was associated with a 41% to 54% decrease in the odds of being on ART, adhering to ART, and achieving viral suppression.¹⁶ Among 6,873 people with HIV enrolled in the CFAR Network of Integrated Clinical Systems (CNICS), a 10-site clinical cohort of people with HIV engaged in care, 9.6% reported housing instability, including 4.6% with unstable housing, 3.3% homelessness, and 1.7% uncertainty about housing stability.¹⁷ In the primary adjusted analysis, houselessness was associated with an 18% lower prevalence of viral suppression (95% confidence interval [CI], 0.77–0.89), and unstable housing was associated with a 6% lower prevalence of HIV viral suppression (95% CI, 0.90–0.98) than with stable housing. In a secondary analysis, houselessness was associated with a 21% lower prevalence of viral suppression among people reporting substance use (95% CI, 0.70–0.90). Interventions supporting housing among people with HIV and SUD can result in improved HIV treatment outcomes (see [Adherence to the Continuum of Care](#)). A randomized controlled trial of a rapid rehousing intervention for people with HIV who were houseless (n = 236; 81% with substance use) found that clients in the Enhanced Housing Placement Assistance arm were more likely to be placed and placed faster, and were twice as likely as the control group to reach or maintain viral suppression (95% CI, 1.1–4.0).^{18,19} An observational study of applicants to a supportive housing program for low-income people with HIV and a mental health condition or SUD (n = 958; 86% with SUD) found that people who achieved stable housing were more likely to engage in HIV care and to achieve viral suppression.²⁰ These data reflect the importance of not only addressing SUD among people with HIV but also understanding the co-occurring structural determinants that contribute to poorer outcomes among people with HIV and SUD.

Screening for Substance Use Disorders

Screening for SUDs should be incorporated into the routine clinical care of all people with HIV. The following questions can be used to screen for drug or alcohol use: “How many times in the past year have you used any drugs (including benzodiazepines, cannabis/cannabinoids, club drugs, opioids, or stimulants) or used a prescription medication for nonmedical reasons?” and “How many times in the past year have you had X or more drinks in a day?” (X is five for men and four for women).²¹ For individuals with liver disease, including active hepatitis B virus (HBV) and/or HCV infection or with metabolic dysfunction–associated steatotic liver disease, any alcohol use is considered unhealthy.

A positive response to either of the two questions above should prompt additional screening with other short screening tools (see the [Screening and Assessment Tools Chart](#) from the National Institute on Drug Abuse). These tools can identify at-risk substance use and guide decisions on appropriate treatment interventions. Currently, insufficient data are available to determine how often people with HIV should be screened for SUDs; however, given the potential negative impact that SUDs may have on people with HIV, it is advisable to ask these questions during every clinical visit.

Health care providers should be nonjudgmental when discussing substance use with people who have HIV (AIII). People with HIV who experience stigma or judgment may lose trust in their health care provider’s advice, avoid future visits, and consequently experience poorer health outcomes.^{22,23} Language is one way in which stigma is communicated, and words such as “addict” and “dirty urine” convey a negative connotation. The Office of National Drug Control Policy, American Medical Association, American Society of Addiction Medicine (ASAM), International Society of Addiction Journal Editors, and others have recommended the adoption of clinical, nonstigmatizing language for substance use, as described by the [National Institute on Drug Abuse](#).

Co-occurring Mental Health Disorders

Many people who use substances have co-occurring mental health disorders, including a history of trauma that may drive or exacerbate their substance use. Conversely, ongoing use of substances

can place individuals at risk for trauma, such as sexual assault and sexual exploitation, which may further exacerbate their substance use.^{8,24} People with SUDs should undergo evaluation and treatment for concurrent mental health disorders using standardized screening instruments (e.g., the [Patient Health Questionnaire-2](#), or PHQ-2, for depression). Where applicable, clinicians should use available behavioral and pharmacological interventions to address mental health concerns, because recommending that people stop substance use without providing treatment for underlying mental health conditions has very limited efficacy.²⁵

Selecting, Initiating, and Maintaining Antiretroviral Therapy

Ongoing substance use is **not** a contraindication for prescribing ART. ART is recommended for all people with HIV to improve their health and to prevent transmission of HIV to others (**AI**), including sexual partners and individuals who share drug paraphernalia. These clinical, community, and individual benefits should encourage health care providers to initiate ART in all people with HIV who use substances. Although effective ART prevents sexual transmission of HIV, its effectiveness in preventing transmission through shared use of needles or other drug paraphernalia remains unknown.

For people actively injecting drugs, engagement in a syringe service program (SSP) can facilitate access and adherence to ART. SSPs primarily provide sterile drug preparation and injection supplies to reduce transmission of HIV, **HBV**, HCV, and other bloodborne, skin, and soft tissue pathogens. As a regular point of contact for people with complex health and social challenges, SSPs also provide opportunities to offer other integrated health-related and social support services,²⁶ including those for treating SUDs.²⁷ For people with HIV, SSPs can be adapted to provide or link to rapid initiation^{28,29} and maintenance of effective ART.²⁹

When selecting ART regimens for individuals who use substances, clinicians should consider potential barriers to adherence (see [Adherence to the Continuum of Care](#)), comorbidities that could impact care (e.g., advanced liver disease from alcohol, **HBV**, or HCV), potential drug–drug interactions, and possible adverse events from ART or substance use. Providers and people with HIV should discuss adherence during multiple, nonjudgmental evaluations. In general, the use of simplified ART regimens should be considered to aid adherence. Once-daily ART regimens (ideally as a single-tablet regimen)³⁰ with high barriers to resistance, low hepatotoxicity, and low potential for drug–drug interactions are preferred for people with SUDs (**AIII**). Adherence counseling should highlight the benefits of ART use, irrespective of concurrent substance use. While a reduction in substance use may improve adherence to ART,^{31,32} ongoing use is **not** a contraindication to ART.

Long-Acting Antiretroviral Therapy

The development of long-acting (LA) injectable ART provides additional options for treatment. The combination of injectable cabotegravir (CAB) and rilpivirine (RPV) is an optimization option for people with HIV who demonstrate engagement in HIV care and who are virally suppressed on oral therapy (see [Optimizing Antiretroviral Therapy in the Setting of Viral Suppression](#)). Current U.S. Food and Drug Administration (FDA) approval for LA CAB/RPV is limited to individuals with expected good adherence and an ability to achieve viral suppression on oral therapy prior to starting LA ART. The LATITUDE study was an open-label randomized trial that compared switching ART to monthly LA CAB/RPV injections versus maintaining oral ART among people with viral suppression who had experienced adherence challenges. Participants who received LA CAB/RPV had lower rates of regimen failure, defined as two consecutive HIV viral load measurements >200 copies/mL, than those who continued oral ART (22.8% vs. 41.2%, respectively; $P = 0.002$). At baseline, 32% of participants reported hazardous alcohol use. During the study, 46% had at least two drugs identified through a urine drug screen. All participants in the LATITUDE study received adherence support throughout the study.³³ It is not known if similar responses can be seen in clinics without the

resources to provide a similar level of adherence support. Missing LA CAB/RPV doses or a delay in receiving scheduled injections may result in emergence of HIV drug resistance.³⁴

The following factors should be considered when contemplating the use of LA CAB/RPV in people with HIV and SUDs:

- Prior to initiation of LA CAB/RPV, providers should review any prior antiretroviral (ARV) history and available resistance-testing results, with special attention to prior use of integrase strand transfer inhibitors (including prior use of LA CAB for pre-exposure prophylaxis) and/or non-nucleoside reverse transcriptase inhibitors, as well as virologic responses during treatment (see [Optimizing Antiretroviral Therapy in the Setting of Viral Suppression](#)).
- For people with viremia, genotypic resistance tests should be obtained and results reviewed before switching to LA CAB/RPV.
- As with all treatment conversations, providers should discuss adherence with their patients during multiple, nonjudgmental evaluations.
- Providers and people with HIV should consider the impact of using LA CAB/RPV in the context of current or past substance use behaviors. Although some people may welcome or even prefer LA CAB/RPV,³⁵ one qualitative study highlighted that using a needle for administering LA CAB/RPV could be a trigger for people with a history of injecting illicit substances.³⁶
- Studies utilizing LA CAB/RPV have included individuals with good adherence before starting the LA ART, but this should not exclude people with SUDs who are struggling with adherence from being considered for LA CAB/RPV. Rather, the clinical team should consider what additional support may be needed to help people with SUDs succeed with LA CAB/RPV and whether using LA ART without established viral suppression is warranted based on preliminary data (see [Virologic Failure](#) and [Adherence to the Continuum of Care](#) for additional details). Case management, patient navigators, and/or peer navigators should be considered to help people with HIV return for follow-up injections.
- Given the often unpredictable lifestyles of some people with SUDs, clinical care teams should be flexible in scheduling injections or accommodating walk-ins for injections. However, it should be stressed that the doses should be given within the FDA dosing recommendation of 7 days before or after the scheduled LA CAB/RPV injection date.
- If LA CAB/RPV injections are missed or delayed by >7 days, suppressive bridging oral ART should be started and continued until LA CAB/RPV injections can be resumed. See [Interruption of Antiretroviral Therapy](#) and [Optimizing Antiretroviral Therapy in the Setting of Viral Suppression](#) for additional considerations.
- As for all people with HIV, HBV status should be evaluated before the initiation of LA CAB/RPV (see [Hepatitis B Virus/HIV Coinfection](#) and [Optimizing Antiretroviral Therapy in the Setting of Viral Suppression](#) for additional details). If not already immune or infected, HBV vaccination should be initiated while considering LA CAB/RPV, including in those with isolated hepatitis B core antibody.
- LA CAB/RPV is **not recommended** for people with HBV/HIV coinfection unless HBV-active drugs (i.e., tenofovir, entecavir) are included in the regimen.
- Because depressive disorders have been associated with LA CAB/RPV, people with SUDs also should be screened for depressive disorders and treated for depression if indicated.³⁷ If depressive disorders worsen while on LA CAB/RPV, reevaluation should occur to determine whether continued therapy with this regimen is advisable.

Importantly, additional research is needed to determine optimal methods for supporting ART adherence (including to LA ARVs) among people with HIV and SUDs. These research studies will need to take into consideration the combination of various interventions (e.g., peer support, case management, pharmacotherapy for SUDs, housing) and the appropriate individual interventions needed to support overall ART adherence.

Impact of Commonly Used Substances on HIV and Antiretroviral Therapy

Health care providers should have a basic understanding of evidence-based pharmacologic and behavioral (e.g., cognitive behavioral therapy, motivational interviewing, motivational enhancement therapy, contingency management) treatments for different substances, including alcohol, benzodiazepines, cannabis and cannabinoids, club drugs, opioids, stimulants (cocaine and methamphetamines), and tobacco. The sections below discuss the impact of these substances on people with HIV and how these substances affect ART use. People with HIV and SUDs should be offered evidence-based pharmacotherapy (e.g., opioid agonist therapy, tobacco cessation treatment, alcohol use disorder treatment) as part of comprehensive HIV care in clinical settings (see [Table 16](#)) (AI). [ASAM](#) provides resources and guidelines to aid clinicians in the management of SUDs.

Alcohol

Epidemiology

Alcohol consumption is common among people with HIV. Recent estimates indicate that >50% of people with HIV in the United States consume any amount of alcohol (range, 54% to 67%).^{38,39} Among a sample of people with HIV across seven university-based HIV clinics in the United States, 27% of people screened positive for unhealthy alcohol use as determined by the AUDIT-C.³⁹ Unhealthy alcohol use includes a spectrum of consumption, including at-risk or hazardous use, heavy episodic use (binge drinking), and alcohol use disorder (AUD).⁴⁰

Risk-Taking Behaviors, the HIV Care Continuum, and Comorbidities

Unhealthy alcohol use has been linked to HIV acquisition because it can increase the frequency of behaviors that put a person at risk for sexual transmission of HIV.⁴¹⁻⁴³ In a meta-analysis of 27 studies, any alcohol use, unhealthy alcohol use, and alcohol use in sexual contexts were all associated with condomless sex among people with HIV.⁴²

In addition, unhealthy alcohol use has been associated with interruptions in all steps of the HIV care continuum, including lower adherence to ART.^{44,45} Studies have demonstrated both temporal and dose-related relationships between alcohol use and adherence, where ART is more likely to be missed on a given drinking day and the day after drinking, with a stronger association on heavy (binge) drinking days.⁴⁶⁻⁴⁸ The negative impact of unhealthy alcohol use on ART adherence is likely multifactorial and driven by the effects of intoxication, ARV regimen complexity, and patient perceptions of adverse interactions between alcohol and ARV drugs.⁴⁹⁻⁵¹ Studies also have demonstrated an association between unhealthy alcohol use and the loss of durable viral suppression,⁵²⁻⁵⁴ greater time spent with a viral load >1,500 copies/mL after ART initiation,⁵⁵ increased risk of viral rebound, lower retention in care,^{56,57} and increased mortality.⁵⁸⁻⁶¹ Unhealthy alcohol use alone (hazardous or AUD) and in combination with other common comorbidities, including viral hepatitis coinfection, can hasten liver fibrosis progression in people with HIV^{62,63} and increase the risk of frailty in older people with HIV. Finally, in general medical populations, unhealthy alcohol use complicates the management of diabetes mellitus, hypertension, mental health

disorders, other substance use, and other chronic diseases, and it increases the risk for pneumonia, osteoporosis, tuberculosis, and several cancers (e.g., liver, head and neck, and breast cancers).

Management of Unhealthy Alcohol Use

Ongoing alcohol use is **not** a contraindication for a person to receive ART. However, treatment for unhealthy alcohol use may improve HIV treatment outcomes. Behavioral and pharmacological treatments for unhealthy alcohol use among people with HIV demonstrate a small but significant reduction in alcohol use⁶⁴⁻⁶⁶ (see additional resources for alcohol management from the [National Institute on Alcohol Abuse and Alcoholism](#) and the [Substance Abuse and Mental Health Services Administration \[SAMHSA\]](#)). The FDA has approved three pharmacotherapies for AUD: naltrexone, disulfiram, and acamprosate (see [Table 16](#) below).

Clinical trials have demonstrated the efficacy of naltrexone in reducing the number of heavy drinking days among those with HIV and among the general population. Naltrexone appears to be safe to use in people with HIV,^{67,68} and it is not associated with significant drug–drug interactions or irreversible hepatotoxicity. However, it is not recommended for individuals with decompensated liver disease and should be used with caution in individuals with elevated transaminase levels. Use of naltrexone in people with HIV and AUD can improve HIV treatment outcomes.⁶⁹ In a randomized placebo-controlled trial of 100 people in prison with HIV who met the criteria for AUD, individuals who were provided depot naltrexone upon release from prison were more likely to achieve viral suppression at 6 months than the placebo group (56.7% vs. 30.3%).⁶⁸

Data on the use of disulfiram and acamprosate among people with HIV are lacking. Notably, integrating treatment for AUD with treatment for HIV has been shown to increase the number of people who receive alcohol treatment medication, counseling, and formal outpatient alcohol treatment services. Integrating HIV and AUD treatments also may improve the likelihood that a person with HIV will achieve viral suppression on ART. A randomized controlled trial of 128 people with HIV and AUD compared an integrated stepped-care model of alcohol treatment in Veterans Administration HIV clinics to traditional HIV care. At the end of treatment (24 weeks), integrated stepped-care resulted in more participants receiving pharmacotherapy for AUD and participating in counseling. Although differences in alcohol use and viral suppression were not seen at 24 weeks, at 52 weeks, integrated stepped-care was significantly associated with an increased number of alcohol-abstinent days, a decrease in the number of drinks per drinking day, and a decreased number of heavy drinking episodes. In addition, the participants in the stepped-care group had increased odds of achieving viral suppression (odds ratio [OR] 5.58; 95% CI, 1.11–27.99).⁷⁰

Liver cirrhosis—whether related to chronic heavy alcohol use, viral hepatitis, or metabolic dysfunction—associated steatotic liver disease—can result in altered metabolism of ARV drugs. For those who have hepatic impairment due to alcohol-related liver disease, ART dosing should follow the recommendations in [Appendix B](#), which are based on Child-Pugh classifications.

Benzodiazepines

Epidemiology

Although the specific epidemiologic data on the prevalence of benzodiazepine use among people with HIV are limited, benzodiazepine misuse is a growing public health concern due to its impact on both morbidity and mortality.⁷¹ Benzodiazepines cause anterograde amnesia, defined as difficulty recalling events after taking the medication. Individuals do not develop tolerance to this neurocognitive effect, and long-term use of benzodiazepines may result in impairment of neurocognitive functioning.⁷²

Risk-Taking Behaviors and the HIV Care Continuum

People who inject drugs and who also use benzodiazepines engage in riskier behaviors than people who inject drugs but do not use benzodiazepines; these behaviors may include engaging in transactional sex, sharing injection equipment with more people, and performing more frequent injections.⁷³ A cohort of 2,802 people who injected drugs was followed from 1996 to 2013. During that time, benzodiazepines were the substances with the greatest association with mortality.⁷⁴ In a study of opioid and benzodiazepine use and all-cause mortality among 64,602 veterans (16,989 with HIV and 47,613 without) from the Veterans Aging Cohort Study (VACS) cohort (October 2008 to September 2009), long-term benzodiazepine receipt was associated with increased mortality regardless of long-term opioid receipt.⁷⁵ The long-term neurocognitive impact of benzodiazepines on ART adherence among people with HIV is unclear, but prescribing a memory-impairing medication to people with HIV who are prone to neurocognitive impairments from other causes may increase the risk of poor ART adherence.⁷⁶ Benzodiazepines also may be used illicitly to counteract the negative side effects of stimulants, such as cocaine and methamphetamine.⁷⁷

Management of Benzodiazepine Use

Repeated use of benzodiazepines can result in physiological dependence and life-threatening withdrawal in some people. When feasible, individuals who chronically use benzodiazepines should be slowly tapered off the benzodiazepines under the supervision of an experienced clinician. Different benzodiazepines have different potencies (e.g., alprazolam is more potent than diazepam) and, therefore, require different tapers in terms of length and graduated decrease in dosage. [The Joint Clinical Practice Guideline on Benzodiazepine Tapering](#) from ASAM provides recommendations for tapering strategies for different benzodiazepines.

Benzodiazepine and Antiretroviral Drug Interactions

Several pharmacological interactions between benzodiazepines and ARV drugs have also been described. For example, some benzodiazepines are cytochrome P450 (CYP) 3A4 substrates; thus, when these benzodiazepines are used with a ritonavir (RTV)-boosted or cobicistat (COBI)-boosted ARV drug [or lenacapavir \(LEN\)](#), their half-lives and concentrations can increase significantly, leading to enhanced and prolonged sedating effects. See the [Liverpool HIV Drug Interaction Checker](#) for available data on benzodiazepine-related interactions.

Cannabis and Cannabinoids

Epidemiology

Both medical and non-medical cannabis (marijuana) use are prevalent among people with HIV.⁷⁸ Cannabis belongs to a class of compounds that activate cannabinoid receptors.⁷⁹ This class, known as cannabinoids, also includes synthetic compounds, such as K2. Since the early 2000s, cannabinoids have become more popular. In 2009, two cannabinoids were reported to the National Forensic Laboratory Information System. By 2015, 84 compounds had been reported.⁸⁰ These compounds most commonly cause tachycardia, agitation, and nausea, but they have a wide range of psychiatric effects, including psychosis and paranoia.⁸¹

Risk-Taking Behaviors and the HIV Care Continuum

Cannabis has not been shown to negatively impact adherence to ART or a person's ability to achieve viral suppression. In one study, among 874 people with HIV, daily cannabis use did not predict lower odds of ART use or achieving an undetectable HIV RNA level, except when combined

with binge drinking.⁸² Data from the Multicenter AIDS Cohort Study have supported the idea that marijuana use does not predict problems with adherence to ART or achieving viral suppression.⁸³ However, in the CNICS cohort, a multisite clinical cohort of people with HIV, increasing cannabis use was associated with more heavy episodic drinking days per month, more cigarettes smoked per day, and more than twice the odds of hazardous alcohol consumption.⁸⁴ Although data are lacking among adults with HIV, the nationally representative 2015 Youth Risk Behavior Survey (which includes data from 15,624 adolescent students in Grades 9 to 12) found that students who had ever used synthetic cannabinoids engaged in riskier activities, including sex, than students who only used marijuana.⁸⁵ Although the available data suggest that the use of marijuana is not associated with decreased adherence to ART,⁸⁶ data are lacking on the impact of synthetic cannabinoids on ART adherence.

Management of Cannabis and Cannabinoid Use

Because of the aforementioned concerns regarding cannabinoid use, particularly the variety of compounds and neuropsychiatric effects, people with HIV should be discouraged from using cannabinoids until more data are available. No pharmacological treatment exists for cannabinoid use disorder; however, behavioral health treatment may be effective for some people.⁸⁷⁻⁸⁹

Club Drugs

Epidemiology

Club drugs are recreational substances that have euphoric or hallucinogenic effects or that are used to enhance sexual experiences.⁶ The use of multiple club drugs or other drugs simultaneously is common. Although these substances are used by many different people with HIV, the majority of data come from MSM with HIV. The use of club drugs in this population has been shown to negatively impact HIV treatment.⁹⁰ Club drugs include MDMA, GHB, ketamine, benzodiazepines (see the [Benzodiazepines](#) section above), and other drugs that are used to enhance sexual experiences (e.g., mephedrone, inhaled nitrates [poppers], and phosphodiesterase-5 inhibitors [PDE5] for erectile dysfunction).

Risk-Taking Behaviors and the HIV Care Continuum

Club drugs have disinhibitory effects. Using club drugs increases the likelihood that a person will engage in high-risk sexual practices, which can increase the risk of HIV transmission. In addition, these disinhibitory effects can lead to poor ART adherence.⁹⁰⁻⁹²

Management of Club Drug Use

Treatment strategies for club drug use have not been well studied in controlled trials.⁹³ No recommended pharmacotherapies exist at this time, and the most common strategy for treating people who use club drugs is to employ the behavioral interventions that are used for other drug use disorders.

Club Drug and Antiretroviral Drug Interactions

MDMA, GHB, ketamine, and methamphetamine all have the potential to interact with ARV drugs because they are metabolized, at least in part, by the CYP450 system.^{91,92} Overdoses secondary to interactions between club drugs (i.e., MDMA or GHB) and protease inhibitor–based ART have been reported.^{92,94} For instance, using PDE5 or ketamine concurrently with CYP3A4 inhibitors, such as RTV, COBI, or LEN, can potentiate the effects of these substances.⁹⁰

Cocaine

See the discussion in the [Stimulants](#) section below.

Opioids

Epidemiology

Opioids remain a significant concern for people with HIV, both for HIV acquisition and as major contributors to morbidity and mortality. Overdose involving opioids is the leading cause of accidental death in the United States.⁹⁵ The appropriate use of opioids while caring for people with HIV and chronic pain is an important component of combating the opioid epidemic, but this subject is beyond the scope of this section. Please refer to additional resources, such as those from the [Centers for Disease Control and Prevention \(CDC\)](#) and the [Infectious Diseases Society of America](#).⁹⁶ To combat the opioid overdose epidemic, health care providers should prescribe naloxone for opioid overdose prevention for all people who are using opioids beyond the short-term treatment of acute pain.^{97,98}

Risk-Taking Behaviors and the HIV Care Continuum

Many people who use opioids start by using opioid tablets (e.g., oxycodone) that are ingested orally or crushed and sniffed. Once tolerance develops, some individuals move from sniffing the crushed tablets to injecting heroin purchased illicitly. This transition from sniffing to injecting dramatically increases the risk of HIV and HCV infection.

Low-cost heroin is often a mix of heroin and higher-potency synthetic opioids, such as fentanyl.⁹⁵ Methamphetamines and cocaine also have been combined with fentanyl, but at a lower rate than heroin.^{99,100} In all instances where fentanyl or other high-potency opioids are added to other drugs, the risk of overdose increases.

Although treatment for an opioid use disorder (OUD) can improve HIV treatment outcomes, it is not a prerequisite for treating HIV, as some people with HIV are able to adhere successfully to ART despite ongoing opioid use. Although ART coverage among people with HIV who injected drugs increased from 58% to 71% between 2009 and 2015,¹⁰¹ and a more recent study suggested 79% in 2022,¹⁰² additional work is needed to improve ART coverage in this population. Data on engagement in care remains mixed for people with HIV who inject drugs. Data from the Johns Hopkins HIV Clinical Cohort (2001–2012) demonstrated that in the early years of the cohort, people who injected drugs were less likely to remain engaged in care; however, this engagement gap had closed by 2012, and the probabilities of both ART usage and viral suppression were similar in the later years of the cohort, regardless of drug injection status.¹⁰³ However, results from the CDC's Medical Monitoring Project suggest that engagement in care for people with HIV who inject drugs remains a challenge.¹⁰⁴

Management of Opioid Use

The FDA has approved three medications for the treatment of OUD that can help decrease or eliminate opioid use, reduce opioid-related morbidity and mortality, and improve HIV clinical outcomes. These medications—collectively termed medications for opioid use disorder—include buprenorphine, methadone, and naltrexone (see [Table 16](#) below). Buprenorphine and methadone are opioid agonists, whereas naltrexone is an opioid antagonist. Buprenorphine and naltrexone have both oral and LA injectable formulations and can be prescribed in the setting of routine HIV clinical care.¹⁰⁵ The requirement for specific training to prescribe buprenorphine was eliminated in 2022; any prescriber with a U.S. Drug Enforcement Administration registration can now prescribe buprenorphine (see the [SAMHSA](#) website for more information). Methadone must be prescribed

through a licensed opioid treatment program (OTP). An [OTP Directory](#) also can be found on the SAMHSA website.

Use of buprenorphine or methadone can lead to reductions in HIV transmission risk behaviors, psychosocial and medical morbidity related to OUD, and criminal behaviors. Both buprenorphine and methadone are cost-effective interventions at the societal level.¹⁰⁶ Although several randomized, controlled clinical trials have demonstrated efficacy for naltrexone when treating OUD, subsequent study results have been disappointing; one meta-analysis revealed that oral naltrexone was equivalent to placebo.¹⁰⁷ An open-label randomized trial comparing extended-release naltrexone and sublingual buprenorphine-naloxone found that extended-release naltrexone was harder to initiate. However, among participants who successfully initiated treatment, relapse rates were similar between medications.¹⁰⁸ In a randomized, placebo-controlled trial in people with both HIV and OUD, participants who received at least three doses of depot naltrexone before discharge from prison achieved longer periods of continuous abstinence after transitioning from prison to the community than those who received either placebo or two or fewer doses of depot naltrexone.⁶⁸ Based on these data, methadone or buprenorphine generally are used as first-line agents for the treatment of OUD among people with HIV. Depot naltrexone can be used as an alternative treatment for people being released recently from prisons or jails when other options are not available.

Important pharmacokinetic (PK) interactions between these medications (particularly methadone) and certain ARV drugs are available in the [Liverpool HIV Drug Interaction Checker](#). As the use of LA injectable medications for OUD and HIV expands, additional studies evaluating PK interactions between these drugs are needed.

Although medications remain the backbone of treatment for OUD, there is growing recognition of the critical importance of the social drivers of health and how they impact the willingness of people to engage in treatment with the medications discussed above. A randomized study assessed the effectiveness of extended-release naltrexone compared to buprenorphine or methadone as OUD treatment in 114 people with HIV, including its association with viral suppression. In a secondary analysis, stable housing, high school–level education or greater, and income stability were associated with a greater reduction in opioid use over time.¹⁰⁹

Xylazine and Other Opioid Adulterants

The opioid drug supply continues to evolve rapidly, with many new adulterants entering the supply. Xylazine—a non-opioid analgesic utilized in veterinary medicine that is a commonly used adulterant in opioids and other substances—has become an emerging drug threat associated with the opioid epidemic.¹¹⁰ Xylazine is a substrate of CYP3A4 and, as such, when used with an ARV regimen including a CYP3A4 inhibitor, such as RTV, COBI, or LEN, may lead to elevated levels and prolonged half-lives of xylazine.¹¹¹ For people with HIV who continuously use opioids in areas with high rates of xylazine-adulterated fentanyl or illegally manufactured fentanyl, providers should weigh the risks and benefits of using ARV drugs with CYP3A4 inhibitors, given potential interactions and the increase in xylazine-associated adverse effects.

Opioid adulterants, such as xylazine, increase the risk of overdose. Although naloxone only reverses opioid effects, that alone may be sufficient to reverse the overdose. This highlights the need for universal access to naloxone and the active prescribing of naloxone by health care providers. The CDC maintains information about xylazine and how to reduce its harm on its website.¹¹²

Medetomidine, an alpha-2 adrenergic agonist sedative, is more potent and longer acting than xylazine. Medetomidine has been detected in the illicit opioid supply in North America since 2021. The CDC reported an outbreak of overdoses in May 2024 in the Chicago area.¹¹³ A report later in 2024 cited data that medetomidine had been found in illicit drug samples in 18 states and the District

of Columbia.¹¹⁴ In 2026, the CDC reported that the prevalence of medetomidine continues to rise at an alarming rate.¹¹⁵ The growing prevalence and medical complications associated with medetomidine warrant vigilance in caring for people with HIV using opioids. Like other alpha-2 adrenergic agonists, medetomidine use can cause sedation, bradycardia, and hypotension. Prolonged sedation following administration of naloxone should prompt consideration of medetomidine. Withdrawal can cause hypertension, anxiety, nausea, vomiting, and alterations in consciousness, which can require emergency or intensive care. Medetomidine is a CYP3A, 2D, and 2E substrate and thus has the potential for significant drug–drug interactions with inhibitors or inducers of these enzymes. The CDC has published recommendations for clinicians.¹¹⁵

Stimulants

Epidemiology

Cocaine and methamphetamine are powerful stimulants that have been associated with multiple detrimental effects among people with HIV, including accelerated disease progression, poor ART adherence, and lack of viral suppression. Powdered cocaine is administered intranasally or intravenously, while freebase cocaine (crack) is smoked. Methamphetamines can be taken orally or rectally, injected, or smoked. Cocaine and methamphetamine are commonly used with other substances, including alcohol, and can be combined with fentanyl, which increases the risk of overdose.^{99,100} Individuals who use stimulants experience a sense of euphoria and may have heightened sexual desire and arousal. This can lead to disinhibited sexual behaviors, increasing the risk of HIV transmission.

The prevalence of stimulant use among people with HIV has been estimated to be 5% to 15% across multiple studies.^{116–118} Methamphetamine use is more common among MSM,¹¹⁹ and increased rates of cocaine use have been observed among ethnic and racial minorities and people with a history of incarceration.¹²⁰

Risk-Taking Behaviors and the HIV Care Continuum

People with HIV who use stimulants may experience multiple negative health consequences, including rapid development of dependence and adverse effects on multiple organ systems, particularly the central nervous and cardiovascular systems.¹²¹ Stimulant use is associated with neurocognitive impairment,¹²² delirium, seizures, hemorrhagic strokes, and mental health disturbances, including anxiety, psychosis, and paranoia.

Stimulant use may independently lead to HIV disease progression, even among people who are taking ART and have achieved viral suppression. Research to identify the cellular mechanisms responsible for this is ongoing, but increased viral replication, direct effects on the immune system that lead to declines in CD4 T lymphocyte cell count, enhanced immune activation, and disruption of the blood-brain barrier, facilitating HIV entry into the brain, have been implicated.^{123–127} Stimulant use has been associated with poor HIV continuum of care outcomes, including suboptimal rates of ART adherence,^{128,129} retention in care, and viral suppression.^{130–132} Lack of viral suppression, combined with the increased likelihood of risky sexual behaviors that occur under the influence of stimulants, poses a threat to the HIV treatment-as-prevention paradigm.¹³³

Management of Stimulant Use

Several pharmacologic and behavioral interventions for stimulant dependence have been investigated, and some trials have included people with HIV. The results of pharmacologic interventions generally have been disappointing. No FDA-approved pharmacotherapy for cocaine use disorder currently exists, despite research on multiple drug classes, including antidepressants,

antipsychotics, anticonvulsants, and dopaminergic medications (e.g., disulfiram).^{134,135} Among people with HIV who use crack and opioids, medications for OUD may improve ART adherence and viral suppression.^{136,137} Limited evidence indicates that some pharmacologic interventions (e.g., methylphenidate, modafinil, bupropion, naltrexone, mirtazapine)^{138,139} can reduce methamphetamine use or cravings. A double-blind, placebo-controlled trial of extended-release injectable naltrexone plus oral extended-release bupropion in adults with moderate or severe methamphetamine use disorder demonstrated a higher response of methamphetamine-free urine samples than with placebo; however, the overall response rate was low.¹⁴⁰ Two double-blind randomized placebo-controlled trials found that daily mirtazapine use in people with methamphetamine use disorder led to reduced methamphetamine-positive urine drug tests, with one trial also demonstrating reduced sexual risk behaviors¹³⁹ and the other demonstrating a reduced number of days with methamphetamine use.¹⁴¹ No specific recommended pharmacotherapy exists to treat stimulant use disorder in people with HIV.

Several behavioral interventions for the management of stimulant use disorder in people with HIV have shown promise in randomized trials. People with HIV who received motivational interviewing sessions, cognitive behavioral therapy, or a combination of the two experienced decreased stimulant use, improved ART adherence, and reduced engagement in sexual transmission risk behaviors.¹⁴² Contingency management has been shown to be effective in decreasing stimulant use among people with HIV. A 12-week pilot study of weekly contingency management among 31 people with HIV and stimulant use disorder in an urban safety-net HIV clinic reported increases in tenofovir-reactive urine tests and stimulant-negative urine tests with the intervention.¹⁴³ At baseline, 55% of the participants had viral suppression. The viral suppression rate increased to 88% for the 26 participants who attended the post-intervention visit. The sustained effects of contingency management on the reduction of stimulant use and improvements in ART adherence and viral suppression are less clear.^{117,144,145} The addition of a positive affect intervention to contingency management, compared with an attention control condition, decreased HIV viral load among gay, bisexual, and other MSM with HIV.¹⁴⁶ Technology-based interventions, such as text messaging, may have a role in supporting ART adherence and decreasing methamphetamine use among people with HIV, but further research is needed.¹⁴⁷ People with HIV who use stimulants benefit most from multidimensional interventions that target substance use, ART adherence, and risky sexual behaviors.¹⁴²

Despite the challenges discussed above, people with HIV who use stimulants can achieve viral suppression with ART¹³² and should be prescribed ART even if stimulant use is ongoing.

Tobacco

Epidemiology

The prevalence of tobacco smoking among people with HIV in the United States is approximately twice that of the general population (33.6% vs. 16.8%).¹⁴⁸ Prevalence is even higher among specific subgroups, including those who use alcohol and/or other drugs, those who have concurrent mental health disorders, and those of a lower socioeconomic status. Although smoking rates are declining overall in the United States, people with HIV are less likely to quit smoking than people in the general population.¹⁴⁸ Although the majority of people who use tobacco in the United States still use combustible products, use of vaporized nicotine (electronic cigarettes or e-cigarettes) has remained prevalent, especially among young adults and people with HIV.^{149,150} In one study of 7,431 people with HIV, use of vaporized nicotine was associated with patient-reported depression and panic symptoms, which may have important implications for quality of life.¹⁵¹

Associated Risks of Tobacco Use and HIV Infection

With respect to substance use and HIV, tobacco smoking is the biggest threat to health-related gains achieved through ART. Among individuals with viral suppression on ART, more years of life may be lost from continued smoking than from HIV infection itself.^{152,153} Tobacco smoking among people with HIV is associated with an increased risk of numerous health conditions, including lung cancer and other smoking-related cancers, cardiovascular disease, and pulmonary disease. In a sample of 17,995 people with HIV on ART in Europe and North America, individuals who smoked had nearly twice the mortality of those who did not (mortality rate ratio 1.94; 95% CI, 1.56–2.41), with significant mortality attributed to cardiovascular disease and non-AIDS-related malignancy.¹⁵² Importantly, tobacco cessation reduces the incidence of cardiovascular disease and smoking-related cancers (although definitive data on lung cancer are not available) and improves quality of life.^{154–156}

Managing Tobacco Use

To maximize the survival benefits of ART, clinicians should consider using evidence-based behavioral and pharmacological^{157–159} cessation strategies when treating people with HIV who smoke tobacco (see the tools and recommendations provided by the [CDC](#) and [U.S. Preventive Services Task Force](#) and recent review).¹⁶⁰ These include (but are not limited to) advising the individual to quit smoking, **using the five A's (ask, advise, assess, assist, and arrange)**, employing motivational interviewing, and referring them to a tobacco quitline. Pharmacotherapies for smoking cessation (nicotine replacement therapy [NRT], bupropion, and varenicline) have few clinically significant interactions with ARV drugs and can lead to enormous reductions in morbidity and mortality if the person is able to stop smoking. Varenicline is a partial nicotine receptor agonist. In comparative studies, varenicline was more effective than bupropion in smoking cessation.^{161,162} Clinical trials among people with HIV have found varenicline to be both effective and safe.^{157,159} In a randomized controlled trial among 179 individuals with HIV who were assigned to receive 12 weeks of behavioral counseling and either varenicline or placebo, varenicline use led to an increase in the percentage of participants who achieved a 7-day abstinence period at 12 weeks (28.1% vs. 12.1%, OR 4.5; 95% CI, 1.83–11.2) and produced higher continuous abstinence between Weeks 9 and 12 (23.6% vs. 10%, OR 4.65; 95% CI, 1.71–12.67) than with placebo.¹⁵⁹ Although significant between-group differences were not observed after 24 weeks, these data support the use of varenicline among people with HIV. **Varenicline and dual NRT (LA plus short-acting NRT) are more effective than single NRT or bupropion, although all of these increase tobacco abstinence.**¹⁶⁰ Varenicline should be used in combination with relapse prevention strategies and other measures for long-term tobacco cessation. **Electronic cigarettes are not FDA approved for the treatment of tobacco use disorder, and insufficient evidence is available to suggest that e-cigarettes reduce the risk of lung cancer compared with combustible tobacco products.**

Table 16. Medications for Treatment of Substance Use Disorders

Medication	Dose and Recommendations	Potential Interaction With ARV Drugs	Comments
Alcohol Use Disorder			
Acamprosate	666 mg PO three times a day <i>or</i> 333 mg PO three times a day for people with CrCl 30–50 mL/min	No significant interaction with ARV drugs expected.	Contraindicated in people with CrCl <30 mL/min
Disulfiram	250 mg PO once daily	Use with caution when prescribing an ARV oral solution that contains ethanol and/or propylene glycol (e.g., FPV, LPV/r, RTV).	Counsel people regarding disulfiram reaction when taken with alcohol; symptoms for the reaction may include flushing, tachycardia, nausea, vomiting, or hypotension.
Naltrexone	50–100 mg PO once daily 380 mg IM every 4 weeks	No significant interaction with ARV drugs expected.	Has the greatest efficacy of all FDA-approved medications for AUD.
Opioid Use Disorder			
Buprenorphine <i>or</i> Buprenorphine/Naloxone (sublingual tablets)	Individualize dosing based on the person's opioid use. See product labels for dosing information.	Potential interaction of buprenorphine with ARV drugs that are CYP inhibitors or inducers. See the Liverpool HIV Drug Interaction Checker .	Verify that the person is using the appropriate technique for sublingual administration before adjusting the dose, because improper administration will result in poor absorption and low drug levels.
Buprenorphine (subcutaneous injection)	Weekly or monthly subcutaneous injection available in various doses. See product label for dosing information.	Potential interaction with ARV drugs that are CYP inhibitors or inducers. See the Liverpool HIV Drug Interaction Checker .	Weekly and monthly formulations are different. Weekly doses cannot be combined to yield an equivalent monthly dose. Because buprenorphine initiation may carry a risk of relapse and subsequent overdose, providing naloxone is strongly recommend.
Methadone	Individualize the dose. People who receive higher doses (>100 mg PO per day) are more likely to remain in treatment.	Potential interaction with ARV drugs that are CYP inhibitors or inducers. See the Liverpool HIV Drug Interaction Checker .	QTc prolongation is a concern at higher doses. Methadone can be prescribed for OUD only by a licensed OTP.

Table 16. Medications for Treatment of Substance Use Disorders

Medication	Dose and Recommendations	Potential Interaction With ARV Drugs	Comments
Naltrexone	50–100 mg PO once daily Depot formulation is a fixed-dose monthly injection.	No significant interaction with ARV drugs expected.	Longer time of continuous abstinence in those who received depot formulation naltrexone compared with placebo after transition from prison to community.
Nicotine Use Disorder			
Nicotine Replacement Therapy	The FDA has approved a wide variety of nicotine replacement products. All formulations are effective.	No significant interaction with ARV drugs expected.	Work with the person to identify the route of delivery that they will use and find most helpful.
Bupropion	Start at 150 mg PO daily for 3 days, then increase to either 150 mg twice daily or 300 mg once daily (use only formulations that are approved for once-daily dosing).	Bupropion is a CYP2D6 inhibitor and a CYP2B6 substrate. See the Liverpool HIV Drug Interaction Checker .	For optimal results, tobacco quit date should occur 1 week after starting therapy.
Varenicline	Titrate the dose based on tolerability until the desired effect is achieved. The goal is to reach a dose of 1 mg PO twice daily. Requires dose adjustment in people with CrCl <30 mL/min.	No significant interaction with ARV drugs expected.	For optimal results, tobacco quit date should occur 1 week after starting therapy.

Key: ARV = antiretroviral; AUD = alcohol use disorder; CrCl = creatinine clearance; CYP = cytochrome P450; FDA = U.S. Food and Drug Administration; FPV = fosamprenavir; IM = intramuscular; LPV/r = lopinavir/ritonavir; OTP = opioid treatment program; OUD = opioid use disorder; PO = orally; QTc = QT corrected for heart rate; RTV = ritonavir

Knowledge Gaps

- Research is needed to assess different strategies integrating SUD treatment and HIV treatment (e.g., telemedicine, artificial intelligence, decision tools) to improve the reach and effectiveness of evidence-based treatment for SUD and HIV.
- Implementation research is needed on how to deliver LA ART with LA treatment for SUDs to improve clinical outcomes of HIV and SUD.
- Research using an effectiveness-implementation hybrid trial design is needed to evaluate different strategies for improving HIV care continuum outcomes among people who use substances.
- More research is needed to assess PK interactions between ART and OUD treatments, including LA and short-acting formulations of both.

- Research is needed to determine whether viral suppression achieved through ART prevents transmission of HIV to needle/injection equipment-sharing partners, analogous to “treatment as prevention” for sexual partners.
- Research is needed to determine the preferred approaches for supporting ART adherence (including to LA ARV drugs) among people with HIV and SUDs.

References

1. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. 2024. Accessed: August 8, 2024. Available at: <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>.
2. Centers for Disease Control and Prevention. HIV diagnoses, deaths, and prevalence: 2026 update. 2026. Available at: <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-and-prevalence-2026.html>.
3. Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD. Reducing the health consequences of opioid addiction in primary care. *Am J Med*. 2013;126(7):565-71. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23664112>.
4. Shiao S, Arpadi SM, Yin MT, Martins SS. Patterns of drug use and HIV infection among adults in a nationally representative sample. *Addict Behav*. 2017;68:39-44. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28088742>.
5. Arrington-Sanders R, Galai N, Falade-Nwulia O, et al. Patterns of polysubstance use in young Black and Latinx sexual minority men and transgender women and its association with sexual partnership factors: the PUSH study. *Subst Use Misuse*. 2024;59(3):317-328. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38146133>.
6. National Institute on Drug Abuse. Club drugs. 2024. Available at: <https://www.drugabuse.gov/drugs-abuse/club-drugs>.
7. Georgiadis N, Katsimpris A, Vatmanidou MA, Vassilakou T, Beloukas A, Sergeantanis TN. Prevalence of chemsex and sexualized drug use among men who have sex with men: a systematic review and meta-analysis. *Drug Alcohol Depend*. 2025;275:112800. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/40759067>.
8. Pakianathan M, Whittaker W, Lee MJ, et al. Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics. *HIV Med*. 2018;19(7):485-490. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29790254>.
9. Kohli M, Hickson F, Free C, Reid D, Weatherburn P. Cross-sectional analysis of chemsex drug use and gonorrhoea diagnosis among men who have sex with men in the UK. *Sex Health*. 2019;16(5):464-472. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30760386>.
10. Ivey K, Bernstein KT, Kirkcaldy RD, et al. Chemsex drug use among a national sample of sexually active men who have sex with men, - American men's internet survey, 2017–2020. *Subst Use Misuse*. 2023;58(5):728-734. Available at: <https://pubmed.ncbi.nlm.nih.gov/36872623>.
11. Guerras JM, Hoyos J, Donat M, et al. Sexualized drug use among men who have sex with men in Madrid and Barcelona: the gateway to new drug use? *Front Public Health*. 2022;10:997730. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36457321>.
12. Strong C, Huang P, Li CW, Ku SW, Wu HJ, Bourne A. HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men. *Lancet HIV*. 2022;9(10):e717-e725. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35926550>.

13. Lemain L, Lever D, Therene-Mouden C, Verdeau R, Barais M, Guillou-Landreat M. Chemsex among men having sex with men: a scoping review on management, support, and harm reduction strategies. *J Sex Res.* 2025;62(3):367-377. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39093301>.
14. Dasgupta S, Tie Y, Lemons-Lyn A, Broz D, Buchacz K, Shouse RL. HIV-positive persons who inject drugs experience poor health outcomes and unmet needs for care services. *AIDS Care.* 2021;33(9):1146-1154. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32985227>.
15. Arum C, Fraser H, Artenie AA, et al. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. *Lancet Public Health.* 2021;6(5):e309-e323. Available at: <https://pubmed.ncbi.nlm.nih.gov/33780656>.
16. Reddon H, Fairbairn N, Grant C, Milloy MJ. Experiencing homelessness and progression through the HIV cascade of care among people who use drugs. *AIDS.* 2023;37(9):1431-1440. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37070552>.
17. Fahey CA, Whitney BM, Drumright LN, et al. Association between housing instability and HIV care outcomes among people with HIV in the United States. *J Acquir Immune Defic Syndr.* 2026; Available at: <https://www.ncbi.nlm.nih.gov/pubmed/42357998>.
18. Towe VL, Wiewel EW, Zhong Y, Linnemayr S, Johnson R, Rojas J. A randomized controlled trial of a rapid re-housing intervention for homeless persons living with HIV/AIDS: impact on housing and HIV medical outcomes. *AIDS Behav.* 2019;23(9):2315-2325. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30879212>.
19. Hall G, Singh T, Lim SW. Supportive housing promotes AIDS-free survival for chronically homeless HIV positive persons with behavioral health conditions. *AIDS Behav.* 2019;23(3):776-783. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30684098>.
20. Wiewel EW, Singh TP, Zhong Y, et al. Housing subsidies and housing stability are associated with better HIV medical outcomes among persons who experienced homelessness and live with HIV and mental illness or substance use disorder. *AIDS Behav.* 2020;24(11):3252-3263. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32180090>.
21. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. *Arch Intern Med.* 2010;170(13):1155-60. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20625025>.
22. Batchelder AW, Foley JD, Wirtz MR, Mayer K, O'Cleirigh C. Substance use stigma, avoidance coping, and missed HIV appointments among MSM who use substances. *AIDS Behav.* 2021;25(5):1454-1463. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32737816>.
23. Stringer KL, Marotta P, Baker E, et al. Substance use stigma and antiretroviral therapy adherence among a drug-using population living with HIV. *AIDS Patient Care STDS.* 2019;33(6):282-293. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31166784>.
24. Marinetti L, Montgomery MA. The use of GHB to facilitate sexual assault. *Forensic Sci Rev.* 2010;22(1):41-59. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26242455>.
25. Basu S, Chwastiak LA, Bruce RD. Clinical management of depression and anxiety in HIV-infected adults. *AIDS.* 2005;19(18):2057-67. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16284454>.

26. Broz D, Carnes N, Chapin-Bardales J, et al. Syringe services programs' role in Ending the HIV Epidemic in the U.S.: why we cannot do it without them. *Am J Prev Med*. 2021;61(5 Suppl 1):S118-S129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34686281>.
27. Suarez E, Jr., Bartholomew TS, Plesons M, et al. Adaptation of the tele-harm reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study. *Ann Med*. 2023;55(1):733-743. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36856571>.
28. Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. *N Engl J Med*. 2016;375(3):229-39. Available at: <https://pubmed.ncbi.nlm.nih.gov/27468059>.
29. Tookes HE, Bartholomew TS, Suarez E, et al. Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs. *Drug Alcohol Depend*. 2021;229(Pt A):109124. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34781096>.
30. Griffith DC, Farmer C, Gebo KA, et al. Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV research network. *HIV Med*. 2019;20(2):169-174. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30561888>.
31. Feldman MB, Kepler KL, Irvine MK, Thomas JA. Associations between drug use patterns and viral load suppression among HIV-positive individuals who use support services in New York City. *Drug Alcohol Depend*. 2019;197:15-21. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30743195>.
32. Nance RM, Trejo MEP, Whitney BM, et al. Impact of abstinence and of reducing illicit drug use without abstinence on human immunodeficiency virus viral load. *Clin Infect Dis*. 2020;70(5):867-874. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30994900>.
33. Rana AI, Zheng L, Castillo-Mancilla J, et al. Cabotegravir plus rilpivirine for persons with HIV and adherence challenges. *N Engl J Med*. 2026;394(9):858-871. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/41707171>.
34. Gandhi M, Hickey M, Imbert E, et al. Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV. *Ann Intern Med*. 2023;176(7):969-974. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37399555>.
35. Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. *Nanomedicine (Lond)*. 2013;8(11):1807-13. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23611617>.
36. Philbin MM, Parish C, Bergen S, et al. A qualitative exploration of women's interest in long-acting injectable antiretroviral therapy across six cities in the Women's Interagency HIV Study: intersections with current and past injectable medication and substance use. *AIDS Patient Care STDS*. 2021;35(1):23-30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33400587>.
37. Food and Drug Administration. Cabenuva. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212888s011lbl.pdf.

38. Williams EC, Joo YS, Lipira L, Glass JE. Psychosocial stressors and alcohol use, severity, and treatment receipt across human immunodeficiency virus (HIV) status in a nationally representative sample of US residents. *Subst Abus.* 2017;38(3):269-277. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27925867>.
39. Crane HM, McCaul ME, Chander G, et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. *AIDS Behav.* 2017;21(7):1914-1925. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28285434>.
40. Saitz R. Clinical practice. Unhealthy alcohol use. *N Engl J Med.* 2005;352(6):596-607. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15703424>.
41. Scott-Sheldon LA, Carey KB, Cunningham K, Johnson BT, Carey MP, Team MR. Alcohol use predicts sexual decision-making: a systematic review and meta-analysis of the experimental literature. *AIDS Behav.* 2016;20 Suppl 1(0 1):S19-39. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26080689>.
42. Shuper PA, Joharchi N, Monti PM, Loutfy M, Rehm J. Acute alcohol consumption directly increases HIV transmission risk: a randomized controlled experiment. *J Acquir Immune Defic Syndr.* 2017;76(5):493-500. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28930769>.
43. Rehm J, Shield KD, Joharchi N, Shuper PA. Alcohol consumption and the intention to engage in unprotected sex: systematic review and meta-analysis of experimental studies. *Addiction.* 2012;107(1):51-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22151318>.
44. Williams EC, McGinnis KA, Edelman EJ, et al. Level of alcohol use associated with HIV care continuum targets in a national U.S. sample of persons living with HIV receiving healthcare. *AIDS Behav.* 2019;23(1):140-151. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29995206>.
45. Vagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. The impact of alcohol use and related disorders on the HIV continuum of care: a systematic review: alcohol and the HIV continuum of care. *Curr HIV/AIDS Rep.* 2015;12(4):421-36. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26412084>.
46. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. *Alcohol Clin Exp Res.* 2005;29(7):1190-7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16046874>.
47. Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. *Alcohol Res Health.* 2010;33(3):280-7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23584069>.
48. Parsons JT, Rosof E, Mustanski B. Patient-related factors predicting HIV medication adherence among men and women with alcohol problems. *J Health Psychol.* 2007;12(2):357-70. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17284499>.
49. Kalichman SC, Grebler T, Amaral CM, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. *Int J Behav Med.* 2014;21(5):811-20. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24085706>.

50. Pellowski JA, Kalichman SC, Kalichman MO, Cherry C. Alcohol-antiretroviral therapy interactive toxicity beliefs and daily medication adherence and alcohol use among people living with HIV. *AIDS Care*. 2016;28(8):963-70. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26964014>.
51. Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. *Alcohol Clin Exp Res*. 2016;40(10):2056-2072. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27696523>.
52. Kelso NE, Sheps DS, Cook RL. The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review. *Am J Drug Alcohol Abuse*. 2015;41(6):479-88. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26286352>.
53. Kahler CW, Liu T, Cioe PA, et al. Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. *AIDS Behav*. 2017;21(7):1825-1835. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27392417>.
54. Cook RL, Zhou Z, Kelso-Chichetto NE, et al. Alcohol consumption patterns and HIV viral suppression among persons receiving HIV care in Florida: an observational study. *Addict Sci Clin Pract*. 2017;12(1):22. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28950912>.
55. Lesko CR, Lau B, Chander G, Moore RD. Time spent with HIV viral load >1500 copies/mL among persons engaged in continuity HIV care in an urban clinic in the United States, 2010–2015. *AIDS Behav*. 2018;22(11):3443-3450. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29541913>.
56. Monroe AK, Lau B, Mugavero MJ, et al. Heavy alcohol use is associated with worse retention in HIV care. *J Acquir Immune Defic Syndr*. 2016;73(4):419-425. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27243904>.
57. Ladak F, Socias E, Nolan S, et al. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting. *Antivir Ther*. 2019;24(1):19-25. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30230474>.
58. DeLorenze GN, Weisner C, Tsai AL, Satre DD, Quesenberry CP, Jr. Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. *Alcohol Clin Exp Res*. 2011;35(2):203-10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21058961>.
59. Canan CE, Lau B, McCaul ME, Keruly J, Moore RD, Chander G. Effect of alcohol consumption on all-cause and liver-related mortality among HIV-infected individuals. *HIV Med*. 2017;18(5):332-341. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27679418>.
60. Eyawo O, McGinnis KA, Justice AC, et al. Alcohol and mortality: combining self-reported (AUDIT-C) and biomarker detected (peth) alcohol measures among HIV infected and uninfected. *J Acquir Immune Defic Syndr*. 2018;77(2):135-143. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29112041>.
61. Fuster D, Moreno C, Sanvisens A, et al. Association between excessive alcohol consumption when starting antiretroviral therapy and long-term mortality in people living with HIV. *J Addict Med*. 2025; Available at: <https://www.ncbi.nlm.nih.gov/pubmed/41337756>.

62. Marcellin F, Roux P, Loko MA, et al. High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort. *Clin Infect Dis*. 2014;59(8):1190-2. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25015913>.
63. Lim JK, Tate JP, Fultz SL, et al. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. *Clin Infect Dis*. 2014;58(10):1449-58. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24569533>.
64. Scott-Sheldon LAJ, Carey KB, Johnson BT, Carey MP, Team MR. Behavioral interventions targeting alcohol use among people living with HIV/AIDS: a systematic review and meta-analysis. *AIDS Behav*. 2017;21(Suppl 2):126-143. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28831609>.
65. McGinnis KA, Skanderson M, Edelman EJ, et al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: a longitudinal analysis. *Drug Alcohol Depend*. 2020;217:108272. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32971391>.
66. Hahn JA, Kane JC, Fatch R, et al. Alcohol interventions for persons with HIV: meta-analysis of randomized controlled trials using phosphatidylethanol and self-report. *Drug Alcohol Depend*. 2025;276:112879. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/40992009>.
67. Edelman EJ, Moore BA, Holt SR, et al. Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: a randomized-controlled trial. *AIDS Behav*. 2019;23(1):211-221. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30073637>.
68. Springer SA, Di Paola A, Azar MM, et al. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. *J Acquir Immune Defic Syndr*. 2018;78(1):43-53. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29373393>.
69. Farhadian N, Moradi S, Zamanian MH, et al. Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review. *Subst Abuse Treat Prev Policy*. 2020;15(1):24. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32188486>.
70. Edelman EJ, Maisto SA, Hansen NB, et al. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. *Lancet HIV*. 2019;6(8):e509-e517. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31109915>.
71. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. *Drug Alcohol Depend*. 2019;200:95-114. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31121495>.
72. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. *CNS Drugs*. 2004;18(1):37-48. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14731058>.
73. Darke S, Hall W, Ross M, Wodak A. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. *Drug Alcohol Depend*. 1992;31(1):31-6. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/1358587>.

74. Walton GR, Hayashi K, Bach P, et al. The impact of benzodiazepine use on mortality among polysubstance users in Vancouver, Canada. *Public Health Rep.* 2016;131(3):491-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27252569>.
75. Weisberg DF, Gordon KS, Barry DT, et al. Long-term prescription of opioids and/or benzodiazepines and mortality among HIV-infected and uninfected patients. *J Acquir Immune Defic Syndr.* 2015;69(2):223-33. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26009831>.
76. Newville H, Roley J, Sorensen JL. Prescription medication misuse among HIV-infected individuals taking antiretroviral therapy. *J Subst Abuse Treat.* 2015;48(1):56-61. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25245428>.
77. Motta-Ochoa R, Bertrand K, Arruda N, Jutras-Aswad D, Roy E. "I love having benzos after my coke shot": the use of psychotropic medication among cocaine users in downtown Montreal. *Int J Drug Policy.* 2017;49:15-23. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28826127>.
78. Pacek LR, Towe SL, Hobkirk AL, Nash D, Goodwin RD. Frequency of cannabis use and medical cannabis use among persons living with HIV in the United States: findings from a nationally representative sample. *AIDS Educ Prev.* 2018;30(2):169-181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29688777>.
79. Haley DF, So-Armah K, Justice AC, et al. Cannabis use disorder among people with and without HIV. *J Addict Med.* 2026;20(1):38-43. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/40358026>.
80. Drug Enforcement Administration Diversion Control Division. Special report: synthetic cannabinoids and synthetic cathinones reported in NFLIS, 2013–2015. 2016. Accessed: May 30, 2019. Available at: https://www.nflis.deadiversion.usdoj.gov/publicationsRedesign.xhtml?ifwid=IPT2hJ_tGoVrXHIAqd96yZVI_la5j234yi1CIVVq:4.
81. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. *Clin Toxicol (Phila).* 2016;54(1):1-13. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26567470>.
82. Lake S, Kerr T, Capler R, Shoveller J, Montaner J, Milloy MJ. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. *Int J Drug Policy.* 2017;42:63-70. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28336000>.
83. Lorenz DR, Dutta A, Mukerji SS, Holman A, Uno H, Gabuzda D. Marijuana use impacts midlife cardiovascular events in HIV-infected men. *Clin Infect Dis.* 2017;65(4):626-635. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28449059>.
84. Whitney BM, Delaney JAC, Drumright LN, et al. Brief report: are changes in cannabis use frequency associated with changes in alcohol use and smoking among people with HIV (PWH) - a substitution question. *Drug Alcohol Depend.* 2025;277:112958. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/41260023>.
85. Clayton HB, Lowry R, Ashley C, Wolkin A, Grant AM. Health risk behaviors with synthetic cannabinoids versus marijuana. *Pediatrics.* 2017;139(4)Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28289138>.

86. Sinha S, McCaul ME, Hutton HE, et al. Marijuana use and HIV treatment outcomes among PWH receiving care at an urban HIV clinic. *J Subst Abuse Treat*. 2017;82:102-106. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29021107>.
87. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. *Cochrane Database Syst Rev*. 2016;2016(5):CD005336. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27149547>.
88. Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. *J Consult Clin Psychol*. 2000;68(5):898-908. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11068976>.
89. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. *J Subst Abuse Treat*. 2001;21(2):55-64; discussion 65-6. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11551733>.
90. Daskalopoulou M, Rodger A, Phillips AN, et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. *Lancet HIV*. 2014;1(1):e22-31. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26423813>.
91. Bracchi M, Stuart D, Castles R, Khoo S, Back D, Boffito M. Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety. *AIDS*. 2015;29(13):1585-92. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26372268>.
92. Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. *Expert Rev Clin Pharmacol*. 2008;1(1):115-27. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24410515>.
93. Colfax G, Guzman R. Club drugs and HIV infection: a review. *Clin Infect Dis*. 2006;42(10):1463-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16619161>.
94. Papaseit E, Vazquez A, Perez-Mana C, et al. Surviving life-threatening mdma (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). *Intensive Care Med*. 2012;38(7):1239-40. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22460853>.
95. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013–2017. *MMWR Morb Mortal Wkly Rep*. 2018;67(5152):1419-1427. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30605448>.
96. Bruce RD, Merlin J, Lum PJ, et al. 2017 HIV Medicine Association of Infectious Diseases Society of America clinical practice guideline for the management of chronic pain in patients living with human immunodeficiency virus. *Clin Infect Dis*. 2017;65(10):1601-1606. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29091230>.
97. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. *MMWR Recomm Rep*. 2022;71(3):1-95. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36327391>.
98. Harris MTH, Weinstein ZM, Walley AY. Medications for opioid use disorder, opioid withdrawal, and opioid overdose: a review. *JAMA*. 2026;335(11):986-998. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/41671014>.

99. Khatri UG, Viner K, Perrone J. Lethal fentanyl and cocaine intoxication. *N Engl J Med*. 2018;379(18):1782. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30380395>.
100. LaRue L, Twillman RK, Dawson E, et al. Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine. *JAMA Netw Open*. 2019;2(4):e192851. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31026029>.
101. Hoots BE, Finlayson TJ, Broz D, Paz-Bailey G, Group NS. Antiretroviral therapy use among HIV-infected people who inject drugs-20 cities, United States, 2009–2015. *J Acquir Immune Defic Syndr*. 2017;75 Suppl 3(Suppl 3):S392-S396. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28604444>.
102. Baugher AR, Wejnert C, Kanny D, et al. Are we ending the HIV epidemic among persons who inject drugs?: key findings from 19 US cities. *AIDS*. 2025;39(12):1813-1819. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/40478920>.
103. Lesko CR, Tong W, Moore RD, Lau B. Retention, antiretroviral therapy use and viral suppression by history of injection drug use among HIV-infected patients in an urban HIV clinical cohort. *AIDS Behav*. 2017;21(4):1016-1024. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27752872>.
104. Wu K, Tie Y, Dasgupta S, Beer L, Marcus R. Injection and non-injection drug use among adults with diagnosed HIV in the United States, 2015–2018. *AIDS Behav*. 2022;26(4):1026-1038. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34536178>.
105. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. *J Acquir Immune Defic Syndr*. 2011;56 Suppl 1(Suppl 1):S22-32. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21317590>.
106. Kresina TF, Bruce RD, McCance-Katz EF. Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users. *Curr HIV Res*. 2009;7(4):354-64. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19601770>.
107. Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri A, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. *Addiction*. 2002;97(10):1241-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12359026>.
108. Lee JD, Nunes EV, Jr., Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (x:Bot): a multicentre, open-label, randomised controlled trial. *Lancet*. 2018;391(10118):309-318. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29150198>.
109. Cook RR, Jaworski EN, Hoffman KA, et al. Treatment initiation, substance use trajectories, and the social determinants of health in persons living with HIV seeking medication for opioid use disorder. *Subst Abus*. 2023;44(4):301-312. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37842910>.
110. Zhu DT, Friedman J, Bourgois P, Montero F, Tamang S. The emerging fentanyl-xylazine syndemic in the USA: challenges and future directions. *Lancet*. 2023;402(10416):1949-1952. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37634523>.
111. Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P. Pharmacokinetics of ketamine and xylazine in young and old sprague-dawley rats. *J Am Assoc Lab Anim Sci*. 2013;52(5):567-70. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24041212>.

112. Centers for Disease Control and Prevention. Drug overdose deaths involving xylazine: United States, 2018–2021. Vol 30. June 2023. Accessed: July 9, 2024. Available at: <https://blogs.cdc.gov/nchs/2023/06/30/7408>.
113. Nham A, Le JN, Thomas SA, et al. Overdoses involving medetomidine mixed with opioids - Chicago, Illinois, May 2024. *MMWR Morb Mortal Wkly Rep*. 2025;74(15):258-265. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/40310760>.
114. Palamar JJ, Krotulski AJ. Medetomidine infiltrates the US illicit opioid market. *JAMA*. 2024;332(17):1425-1426. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39230918>.
115. Centers for Disease Control and Prevention. Medetomidine in the U.S. Illegal fentanyl supply increasing risk for overdose and severe withdrawal syndrome. 2026. Available at: <https://www.cdc.gov/han/php/notices/han00527.html>.
116. Hartzler B, Dombrowski JC, Crane HM, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. *AIDS Behav*. 2017;21(4):1138-1148. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27738780>.
117. Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. *Am J Public Health*. 2013;103(8):1457-67. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23763417>.
118. Rosen MI, Black AC, Arnsten JH, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. *AIDS Behav*. 2013;17(1):142-7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22246513>.
119. Vu NT, Maher L, Zablotska I. Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis. *J Int AIDS Soc*. 2015;18(1):19273. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25609214>.
120. Chitsaz E, Meyer JP, Krishnan A, et al. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. *AIDS Behav*. 2013;17 Suppl 2(0 2):S118-27. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23673792>.
121. Kevil CG, Goeders NE, Woolard MD, et al. Methamphetamine use and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2019;39(9):1739-1746. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31433698>.
122. Mediouni S, Marcondes MC, Miller C, McLaughlin JP, Valente ST. The cross-talk of HIV-1 tat and methamphetamine in HIV-associated neurocognitive disorders. *Front Microbiol*. 2015;6:1164. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26557111>.
123. Tyagi M, Weber J, Bukrinsky M, Simon GL. The effects of cocaine on HIV transcription. *J Neurovirol*. 2016;22(3):261-74. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26572787>.
124. Dash S, Balasubramaniam M, Villalta F, Dash C, Pandhare J. Impact of cocaine abuse on HIV pathogenesis. *Front Microbiol*. 2015;6:1111. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26539167>.

125. Carrico AW, Flentje A, Kober K, et al. Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. *Brain Behav Immun*. 2018;71:108-115. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29679637>.
126. Carrico AW, Cherenack EM, Roach ME, et al. Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. *AIDS*. 2018;32(6):767-771. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29369159>.
127. Ross EJ, Williams RS, Viamonte M, et al. Overamped: stimulant use and HIV pathogenesis. *Curr HIV/AIDS Rep*. 2023;20(6):321-332. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37971597>.
128. Lai HH, Kuo YC, Kuo CJ, et al. Methamphetamine use associated with non-adherence to antiretroviral treatment in men who have sex with men. *Sci Rep*. 2020;10(1):7131. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32346081>.
129. Ma J, Delaney JAC, Ruderman SA, et al. Severity and number of substances used are independently associated with antiretroviral therapy adherence over time among people with HIV in the current treatment era. *AIDS Behav*. 2025;29(2):468-479. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39465466>.
130. Goodman-Meza D, Shoptaw S, Weiss RE, et al. Methamphetamine use drives decreases in viral suppression for people living with HIV released from a large municipal jail: results of the LINK LA clinical trial. *Drug Alcohol Depend*. 2019;202:178-184. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31352308>.
131. Fulcher JA, Javanbakht M, Shover CL, et al. Comparative impact of methamphetamine and other drug use on viral suppression among sexual minority men on antiretroviral therapy. *Drug Alcohol Depend*. 2021;221:108622. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33631545>.
132. Carrico AW, Hunt PW, Neilands TB, et al. Stimulant use and viral suppression in the era of universal antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2019;80(1):89-93. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30272634>.
133. Jin H, Ogunbajo A, Mimiaga MJ, et al. Over the influence: the HIV care continuum among methamphetamine-using men who have sex with men. *Drug Alcohol Depend*. 2018;192:125-128. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30248558>.
134. Minozzi S, Amato L, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. *Cochrane Database Syst Rev*. 2015;2015(5):CD003352. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26014366>.
135. Minozzi S, Cinquini M, Amato L, et al. Anticonvulsants for cocaine dependence. *Cochrane Database Syst Rev*. 2015;2015(4):CD006754. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25882271>.
136. Hayashi K, Wood E, Kerr T, et al. Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. *BMC Infect Dis*. 2016;16(1):455. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27568002>.

137. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. *Drug Alcohol Depend.* 2011;113(2-3):192-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20832196>.
138. Bruce RD. Addiction. In: Grant I, Gendelman HE, Grant I, et al, eds. *The neurology of AIDS (3rd edition)*. Oxford University Press; 2011:581–598:chap 7.9. Available at: <https://doi.org/10.1093/med/9780195399349.003.0046>.
139. Coffin PO, Santos GM, Hern J, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. *JAMA Psychiatry.* 2020;77(3):246-255. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31825466>.
140. Trivedi MH, Walker R, Ling W, dela Cruz A. Bupropion and naltrexone in methamphetamine use disorder. *N Engl J Med.* 2021;384:140-153. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa2020214>.
141. McKetin R, Shoptaw S, Saunders L, et al. Mirtazapine for methamphetamine use disorder: a randomized clinical trial. *JAMA Psychiatry.* 2026;83(6):581-589. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/41920558>.
142. Wechsberg WM, Golin C, El-Bassel N, Hopkins J, Zule W. Current interventions to reduce sexual risk behaviors and crack cocaine use among HIV-infected individuals. *Curr HIV/AIDS Rep.* 2012;9(4):385-93. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22872433>.
143. Appa A, Steiner G, Baral S, et al. Integrating HIV and stimulant-use disorder treatment: a pilot implementation effectiveness trial of contingency management in HIV care. *Clin Infect Dis.* 2026;82(4):e728-e734. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/41505433>.
144. Carrico AW, Gomicronmez W, Jain J, et al. Randomized controlled trial of a positive affect intervention for methamphetamine users. *Drug Alcohol Depend.* 2018;192:8-15. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30195243>.
145. Burch AE, Rash CJ, Petry NM. Cocaine-using substance abuse treatment patients with and without HIV respond well to contingency management treatment. *J Subst Abuse Treat.* 2017;77:21-25. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28476266>.
146. Carrico AW, Neilands TB, Dilworth SE, et al. Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine. *J Int AIDS Soc.* 2019;22(12):e25436. Available at: <https://pubmed.ncbi.nlm.nih.gov/31860172>.
147. Moore DJ, Pasipanodya EC, Umlauf A, et al. Individualized texting for adherence building (iTAB) for methamphetamine users living with HIV: a pilot randomized clinical trial. *Drug Alcohol Depend.* 2018;189:154-160. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29958127>.
148. Frazier EL, Sutton MY, Brooks JT, Shouse RL, Weiser J. Trends in cigarette smoking among adults with HIV compared with the general adult population, United States - 2009–2014. *Prev Med.* 2018;111:231-234. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29550303>.
149. Agaku I. Tobacco product use among U.S. adults, 2023–2024. *NEJM Evid.* 2026;5(4):EVIDpha2500339. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/41805408>.

150. Thorne SL, Caraballo RS, Tie Y, Harris NS, Shouse RL, Brooks JT. E-cigarette use among persons with diagnosed HIV in the U.S. *AJPM Focus*. 2023;2(1). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37206980>.
151. Hahn AW, Ruderman SA, Nance RM, et al. Vaporized nicotine (e-cigarette) and tobacco smoking among people with HIV: use patterns and associations with depression and panic symptoms. *J Acquir Immune Defic Syndr*. 2023;92(3):197-203. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36399783>.
152. Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. *AIDS*. 2015;29(2):221-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25426809>.
153. Reddy KP, Parker RA, Losina E, et al. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. *J Infect Dis*. 2016;214(11):1672-1681. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27815384>.
154. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). *HIV Med*. 2011;12(7):412-21. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21251183>.
155. Vidrine DJ, Arduino RC, Gritz ER. The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS. *AIDS Patient Care STDS*. 2007;21(9):659-66. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17919093>.
156. Shepherd L, Ryom L, Law M, et al. Cessation of cigarette smoking and the impact on cancer incidence in human immunodeficiency virus-infected persons: the Data Collection on Adverse Events of Anti-HIV Drugs study. *Clin Infect Dis*. 2019;68(4):650-657. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29912335>.
157. Mercie P, Arsandaux J, Katlama C, et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 inter-activ): a randomised controlled phase 3 clinical trial. *Lancet HIV*. 2018;5(3):e126-e135. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29329763>.
158. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet*. 2016;387(10037):2507-20. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27116918>.
159. Ashare RL, Thompson M, Serrano K, et al. Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV. *Drug Alcohol Depend*. 2019;200:26-33. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31082665>.
160. Reddy KP, Kruse GR, Lee S, Shuter J, Rigotti NA. Tobacco use and treatment of tobacco dependence among people with human immunodeficiency virus: a practical guide for clinicians. *Clin Infect Dis*. 2022;75(3):525-533. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34979543>.
161. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):47-55. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16820546>.

162. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion sr on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. *Psychopharmacology (Berl)*. 2008;197(3):371-7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18084743>.